Infectious Diseases (all articles) | Page 54 of 298 | Links Medicus Content Curation & Alerts in Medicine

Pictorial Review | Extrapulmonary tuberculosıs: an old but resurgent problem.

9 Mar, 2022 | 08:33h | UTC

Extrapulmonary tuberculosıs: an old but resurgent problem – Insights into Imaging

RCT: Azithromycin is not effective for the prevention of recurrent wheeze following severe respiratory syncytial virus bronchiolitis.

8 Mar, 2022 | 08:49h | UTC

Azithromycin to Prevent Recurrent Wheeze Following Severe Respiratory Syncytial Virus Bronchiolitis – NEJM Evidence

Commentaries:

Study finds azithromycin use during RSV not useful in preventing recurrent wheezing, may cause harm – Vanderbilt University Medical Center

Antibiotic doesn’t prevent future wheezing in babies hospitalized with RSV – Washington University in St. Louis

Commentary on Twitter

This RCT tested oral azithromycin vs placebo to reduce recurrent wheeze (RW) in 1-18-month-olds hospitalized with acute severe RSV bronchiolitis. Azithromycin did not reduce occurrence of RW and may increase risk of RW in some groups. #AAAAI22 #Asthma #EBM https://t.co/jYcBuiQ8aY pic.twitter.com/u65NbQaIlX

— NEJM Evidence (@NEJMEvidence) February 28, 2022

How long does protective immunity against COVID-19 last after infection or vaccination? Two immunologists explain.

8 Mar, 2022 | 08:56h | UTC

How long does protective immunity against COVID-19 last after infection or vaccination? Two immunologists explain – The Conversation

Study shows the number of covid-19 infections missed by lateral flow tests “substantial enough to be of clinical importance”.

8 Mar, 2022 | 08:57h | UTC

News Release: Number of covid-19 infections missed by lateral flow tests “substantial enough to be of clinical importance,” warn experts – BMJ

Original Study: SARS-CoV-2 antigen lateral flow tests for detecting infectious people: linked data analysis – The BMJ

Commentaries:

Lateral flow tests may be missing ‘substantial’ number of COVID-19 infections – Imperial College London

Self-testing for asymptomatic non-contacts using rapid antigen tests—is this leading to a cost effective reduction in infection transmission? – The BMJ

[News release – not published yet] New Sanofi and GSK vaccine demonstrates strong protection against severe Covid-19 in clinical trials.

8 Mar, 2022 | 08:53h | UTC

Commentary: New vaccine demonstrates strong protection against severe Covid-19 in clinical trials – CNN

News Release: Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine

The next variant: three key questions about what’s after Omicron.

8 Mar, 2022 | 08:54h | UTC

The next variant: three key questions about what’s after Omicron – Nature

Systematic Review: Anticoagulants for people hospitalized with COVID‐19.

7 Mar, 2022 | 00:48h | UTC

Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library

Summary: Do blood thinners prevent people who are hospitalised with COVID-19 from developing blood clots? – Cochrane Library

COVID-19: How Omicron overtook Delta in three charts.

7 Mar, 2022 | 00:46h | UTC

COVID-19: How Omicron overtook Delta in three charts – Nature

Review articles: Cutaneous manifestations of SARS-CoV-2 infection.

7 Mar, 2022 | 00:38h | UTC

Cutaneous Manifestations of SARS-CoV-2 Infection – American Journal of Clinical Dermatology

Common skin signs of COVID-19 in adults: An update – Cleveland Clinic Journal of Medicine

The Lancet Series: Ageing with HIV.

7 Mar, 2022 | 00:35h | UTC

Homepage: Ageing with HIV

Editorials:

Ageing with HIV

Time to tackle late diagnosis

Series:

Delayed presentation of HIV among older individuals: a growing problem

How health systems can adapt to a population ageing with HIV and comorbid disease

Biological ageing with HIV infection: evaluating the geroscience hypothesis

Intersectionality of stigmas and health-related quality of life in people ageing with HIV in China, Europe, and Latin America

RCT: Efficacy and safety of switching to the 2-drug regimen Dolutegravir/Lamivudine vs. continuing a 3- or 4-Drug regimen for maintaining virologic suppression in adults living with HIV-1.

7 Mar, 2022 | 00:32h | UTC

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With HIV-1: Week 48 Results From the Phase 3, Non-inferiority SALSA Randomized Trial – Clinical Infectious Diseases

WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients with skin and soft tissue infections.

7 Mar, 2022 | 00:09h | UTC

WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients with skin and soft tissue infections – World Journal of Emergency Surgery

[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.

4 Mar, 2022 | 10:09h | UTC

News Release: RECOVERY trial shows Baricitinib reduces deaths in patients hospitalised with COVID-19 – University of Oxford

Original study: Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

Commentaries:

Arthritis drug reduces mortality in severe COVID-19, huge clinical trial finds – Science

Covid-19: Anti-inflammatory treatment baricitinib reduces deaths in patients admitted to hospital, finds trial – The BMJ

Another life-saving Covid drug identified – BBC

WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.

RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.

Randomized trial: Baricitinib plus remdesivir reduce recovery time in patients with COVID-19

Commentary from the author on Twitter (thread – click for more)

RECOVERY pre-print: Baricitinib

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis https://t.co/g0cNjaBzEL

— Martin Landray (@MartinLandray) March 3, 2022

Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.

4 Mar, 2022 | 10:07h | UTC

Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis – The Lancet

Invited Commentary: Understanding of COVID-19 from infection–fatality ratio – The Lancet

Quantifying the effects of the COVID-19 pandemic on gender equality on health, social, and economic indicators.

4 Mar, 2022 | 10:04h | UTC

Quantifying the effects of the COVID-19 pandemic on gender equality on health, social, and economic indicators: a comprehensive review of data from March, 2020, to September, 2021 – The Lancet

Commentaries:

Gender equality and COVID-19: act now before it is too late – The Lancet

Social and economic effects of the COVID-19 pandemic threaten to reverse progress towards gender equality: study – The Lancet

Commentary on Twitter (thread – click for more)

NEW—The social & economic effects of the #COVID19 pandemic threaten to reverse progress in #GenderEquality by widening gender gaps that already existed in employment, education & gender-based violence, according to our new study in @TheLancet
🔗https://t.co/TCXStNPgRV pic.twitter.com/RAuDBRaNS7

— Institute for Health Metrics and Evaluation (IHME) (@IHME_UW) March 3, 2022

Updated WHO guidance conditionally recommends Molnupiravir for patients with non-severe covid-19 at highest risk of hospitalization.

4 Mar, 2022 | 09:57h | UTC

BMJ News Release: WHO recommends antiviral drug for patients with non-severe covid-19 at highest risk of hospital admission – BMJ

WHO News Release: WHO updates its treatment guidelines to include molnupiravir

See updated guidance: A living WHO guideline on drugs for covid-19 – BMJ

Editorial (just published): Molnupiravir’s authorisation was premature – The BMJ

RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

M-A: Efficacy of covid-19 vaccines in immunocompromised patients.

4 Mar, 2022 | 10:01h | UTC

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis – The BMJ

News Release: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom

Commentary on Twitter

NEW RESEARCH: Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, suggests new research https://t.co/l2IWfSb0zd @sundar__raghav

— The BMJ (@bmj_latest) March 3, 2022

Carbapenem-resistant Acinetobacter Baumannii: colonization, infection and current treatment options.

4 Mar, 2022 | 08:31h | UTC

Carbapenem-resistant Acinetobacter baumannii: Colonization, Infection and Current Treatment Options – Infectious Diseases and Therapy

IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections – Clinical Microbiology and Infection

European guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli.

IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.

Review: Therapeutic strategies for emerging multidrug-resistant Pseudomonas Aeruginosa.

4 Mar, 2022 | 08:32h | UTC

Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa – Infectious Diseases and Therapy

IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections – Clinical Microbiology and Infection

European guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli.

IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.

WHO: COVID-19 pandemic triggers a 25% increase in the prevalence of anxiety and depression worldwide.

3 Mar, 2022 | 09:44h | UTC

News Release: COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide – World Health Organization

Scientific Brief: Mental health and COVID-19: Early evidence of the pandemic’s impact – World Health Organization

Commentary on Twitter (thread – click for more)

🆕 #COVID19 pandemic triggers 25% increase in prevalence of anxiety & depression worldwide: New WHO publication
More: https://t.co/QFiH7j312f #MentalHealth

📷: Getty Images/J. Paget pic.twitter.com/iX15sbHXcW

— World Health Organization (WHO) (@WHO) March 2, 2022

M-A: Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19.

3 Mar, 2022 | 08:49h | UTC

Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis – BMJ Medicine

Editorial: Treatment of severe covid-19 with interleukin 6 receptor inhibition – BMJ Medicine

Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.

3 Mar, 2022 | 08:43h | UTC

Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong – JAMA Pediatrics

Commentary: Study: Dosing change could reduce COVID-19 vaccine heart side effect in teens – UPI

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations.

3 Mar, 2022 | 08:46h | UTC

COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations – Nature Reviews Rheumatology

Commentary on Twitter

Our latest #Review is online now. #COVID-19 risks, outcomes and treatment considerations in #rheumatic disease.

Read it for #free here: https://t.co/WsmuyoFNGT @philipcrobinson pic.twitter.com/I4RWh0Gftr

— NatRevRheumatol (@NatRevRheumatol) February 28, 2022

RCT: Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis.

3 Mar, 2022 | 08:40h | UTC

Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial – Intensive Care Medicine

Commentary on Twitter

Therapeutic drug monitoring‑guided pip/tazo infusion vs fixed dose in #sepsis, TARGET RCT:
🧪no significant difference in mean SOFA
⬇️28-day mortality + ⬆️ clinical/microbiological cure if TDM (no statistical significance)
Results https://t.co/cLS1OQ173I
⬇️Below visual abstract pic.twitter.com/jRjzfNLj1T

— Intensive Care Medicine (@yourICM) March 1, 2022